INVO Bioscience, Inc. (INVO)

INVO Bioscience, Inc. (INVO) Healthcare & Pipeline Overview

INVO Bioscience, Inc. is a commercial-stage fertility company pioneering assisted reproductive technology with its INVOcell device. This innovative solution enables in vivo fertilization and early embryo development, distinguishing its approach within the global fertility market by offering a unique, patient-centric alternative to conventional methods.

What Is the Investment Thesis for INVO?

INVO Bioscience, Inc. presents a unique proposition within the assisted reproductive technology (ART) market, primarily driven by its innovative INVOcell device. The company's core value driver is its ability to offer an in vivo fertilization and early embryo development solution, which differentiates it from traditional in vitro fertilization (IVF). This approach could appeal to patients seeking a more natural process and potentially offer cost efficiencies for clinics by reducing reliance on extensive laboratory infrastructure. Key growth catalysts include the ongoing expansion of INVOcell adoption in existing markets and potential entry into new geographic territories, capitalizing on the rising global demand for fertility treatments. The company's commercial-stage status indicates a foundation for revenue generation, though it currently operates with a significant negative profit margin of -340.9%. The gross margin of 29.1% suggests some operational efficiency at the product level. However, investors should note the company's small market capitalization and a Beta of 1.44, indicating higher volatility compared to the broader market. The ability to scale commercial operations and achieve profitability will be critical in realizing the investment potential of its distinctive technology.

Based on FMP financials and quantitative analysis

INVO Key Highlights

• Market Capitalization: $0.00B, reflecting its status as a small-cap company within the medical devices sector.
• Profit Margin: -340.9%, indicating significant current unprofitability as a commercial-stage enterprise.
• Gross Margin: 29.1%, demonstrating a positive margin at the product level before accounting for operating expenses.
• Beta: 1.44, suggesting higher volatility in its stock price performance relative to the broader market.
• Employees: 25, highlighting a lean operational structure for a company developing and commercializing a medical device.

Who Are INVO's Competitors?

INVO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INVO's Key Strengths?

• Unique INVOcell technology offering in vivo fertilization.
• Commercial-stage company with a tangible product.
• Potential for a more natural and patient-friendly treatment option.
• Addresses a growing global market for fertility solutions.

What Are INVO's Weaknesses?

• Significant negative profit margin (-340.9%).
• Small market capitalization and employee base (25).
• Reliance on a single flagship product (INVOcell).
• Higher market volatility indicated by a Beta of 1.44.

What Could Drive INVO Stock Higher?

• Expansion of INVOcell into new international markets, potentially through new distribution agreements, aiming to broaden global reach.
• Increasing adoption rates of INVOcell by fertility clinics globally, leading to higher sales volumes and market penetration.
• Positive clinical outcomes and patient testimonials further validating the efficacy and benefits of in vivo fertilization, driving demand.
• Potential strategic partnerships with larger healthcare networks or pharmaceutical companies to broaden INVOcell's reach and accessibility.
• Efforts to improve the company's financial performance, including strategies to reduce the negative profit margin and achieve profitability.

What Are the Key Risks for INVO?

• Financial-distress signal — its Altman Z-Score of -5.39 sits in the distress zone (elevated bankruptcy risk).
• Significant negative profit margin of -340.9%, indicating persistent operational losses that require substantial capital to sustain.
• Intense competition from well-established traditional in vitro fertilization (IVF) providers and other emerging assisted reproductive technology solutions.
• Market acceptance challenges for a novel medical device, requiring continuous education, clinical validation, and demonstration of value to healthcare providers and patients.
• Regulatory hurdles and compliance costs associated with obtaining and maintaining approvals in multiple international healthcare markets, which can be complex and time-consuming.
• Reliance on a single primary product, INVOcell, making the company vulnerable to market shifts, technological obsolescence, or product-specific issues without significant diversification.

What Are the Growth Opportunities for INVO?

• Increased Market Penetration in Existing Geographies: INVO Bioscience has an opportunity to deepen its market presence in regions where INVOcell is already commercially available. This involves expanding partnerships with fertility clinics, increasing physician and patient awareness through targeted marketing and education, and demonstrating positive clinical outcomes to drive adoption. As a commercial-stage company, the focus on converting initial interest into sustained usage and expanding the number of cycles performed using INVOcell within existing clinics is crucial. The global fertility services market is projected to continue its growth trajectory, offering a substantial addressable market for INVOcell to capture a larger share through effective commercialization strategies.
• Geographic Expansion into New International Markets: The global demand for assisted reproductive technology is widespread, presenting a significant opportunity for INVO Bioscience to expand its commercial footprint beyond current operational areas. Entering new countries or regions requires navigating diverse regulatory landscapes, establishing distribution networks, and adapting to local healthcare systems and patient needs. Successful expansion could unlock access to millions of potential patients and clinics, particularly in emerging markets where access to traditional, high-cost IVF might be limited. Strategic partnerships with local healthcare providers or distributors would be key to efficiently penetrating these new territories and scaling operations.
• Enhanced Patient Accessibility and Affordability: The INVOcell offers a potentially more affordable and less complex alternative to traditional IVF, which can be a significant barrier for many patients due to high costs and intensive clinic visits. By emphasizing the cost-effectiveness and simplified procedure of INVOcell, INVO Bioscience can tap into a broader patient demographic, including those who might have previously been unable to afford or access fertility treatments. This strategy involves working with clinics to offer competitive pricing models and potentially advocating for insurance coverage, thereby expanding the overall market for ART by making it more inclusive.
• Strategic Partnerships with Fertility Clinic Networks: Forming alliances with large fertility clinic networks or hospital groups could significantly accelerate the adoption and distribution of INVOcell. These partnerships can provide immediate access to a wide patient base, established clinical infrastructure, and experienced medical professionals. Collaborations could involve training programs for clinic staff, joint marketing initiatives, and integration of INVOcell into standard treatment protocols. Such strategic alliances would not only boost sales volumes but also enhance the credibility and clinical acceptance of INVOcell within the broader fertility community, leveraging the partners' existing market influence.
• Product Development and Technology Enhancements: While INVOcell is the flagship product, ongoing research and development to enhance its features, expand its indications, or develop complementary technologies could create new growth avenues. This might include improving the device's design for easier use, exploring applications for different infertility causes, or integrating digital health solutions to support patients and clinics. Continuous innovation ensures that INVO Bioscience remains competitive and responsive to evolving clinical needs and technological advancements in the ART space, potentially leading to new revenue streams and strengthening its intellectual property portfolio.

What Opportunities Does INVO Have?

• Expanding global demand for assisted reproductive technologies.
• Geographic expansion into new international markets.
• Increased adoption due to potential cost-effectiveness and accessibility.
• Strategic partnerships with fertility clinic networks.

What Threats Does INVO Face?

• Intense competition from established traditional IVF providers.
• Regulatory hurdles and compliance costs in different markets.
• Funding challenges for a small, unprofitable company.
• Market acceptance and physician adoption rates for a novel technology.

What Are INVO's Competitive Advantages?

• Proprietary INVOcell technology enabling in vivo fertilization, differentiating it from traditional IVF.
• Regulatory approvals for INVOcell, creating a barrier to entry for similar devices.
• Potential for a more natural and patient-centric fertility treatment experience.
• Cost-effectiveness advantages for clinics and patients compared to conventional IVF infrastructure.

What Does INVO Do?

INVO Bioscience, Inc. is a commercial-stage fertility company dedicated to providing accessible and effective assisted reproductive technology (ART) solutions globally. Founded in 2007 and headquartered in Sarasota, Florida, the company has focused on developing a distinct approach to fertility treatment. Its flagship product, the INVOcell, is a medical device designed to allow fertilization and early embryo development to occur in vivo, meaning within the woman's body, rather than in an external laboratory setting. This method aims to mimic natural physiological conditions, potentially offering a more natural and patient-friendly experience compared to traditional in vitro fertilization (IVF). The company's evolution since its founding has centered on the clinical development, regulatory approval, and commercialization of the INVOcell. By enabling the initial stages of embryo development to take place inside the vaginal cavity, INVO Bioscience seeks to address several aspects of fertility care, including potentially reducing the complexity and cost associated with conventional IVF procedures. This innovative approach positions INVO Bioscience as a key player in the evolving landscape of fertility treatments, catering to a growing global demand for ART solutions. The company's strategy involves expanding the availability and adoption of INVOcell through partnerships with fertility clinics and healthcare providers worldwide, aiming to make advanced fertility care more accessible to a broader patient population. The INVOcell system offers a potentially less resource-intensive option for clinics, as it reduces the need for extensive laboratory infrastructure and specialized personnel typically required for traditional IVF. This could translate into lower treatment costs for patients, thereby broadening access to fertility care for individuals and couples who might otherwise be deterred by the high expenses of conventional methods. INVO Bioscience's focus remains on establishing INVOcell as a viable and preferred alternative in the ART market, leveraging its unique physiological approach to differentiate itself from established competitors.

What Products and Services Does INVO Offer?

• Develops and commercializes assisted reproductive technology (ART) solutions.
• Offers INVOcell, a medical device for fertility treatment.
• Enables fertilization and early embryo development to occur in vivo (within the woman's body).
• Provides an alternative to traditional in vitro fertilization (IVF).
• Aims to make fertility treatment potentially more accessible and patient-centric.
• Operates as a commercial-stage company globally.
• Focuses on the medical devices segment of the healthcare industry.

How Does INVO Make Money?

• Sells the INVOcell medical device directly to fertility clinics and healthcare providers.
• Generates revenue from the sales and distribution of its proprietary fertility solution.
• Potentially offers training and support services for clinics adopting the INVOcell system.
• Aims to expand market share through commercialization efforts and strategic partnerships.

What Industry Does INVO Operate In?

INVO Bioscience, Inc. operates within the dynamic and growing global healthcare sector, specifically targeting the medical devices industry with a focus on assisted reproductive technology (ART). The ART market is characterized by increasing demand driven by factors such as delayed parenthood, rising infertility rates, and greater awareness and acceptance of fertility treatments. Traditional in vitro fertilization (IVF) dominates this landscape, involving complex laboratory procedures. INVO Bioscience positions itself as an innovator by offering the INVOcell, a device that facilitates in vivo fertilization, providing an alternative to conventional IVF. This approach aims to differentiate the company by potentially offering a more natural, patient-centric, and possibly more cost-effective solution. While the market is competitive with established IVF clinics and device manufacturers, INVO Bioscience's unique technology allows it to carve out a niche. The broader trend towards personalized and less invasive medical procedures could favor the adoption of solutions like INVOcell, provided it demonstrates comparable efficacy and gains wider clinical acceptance.

Who Are INVO's Key Customers?

• Fertility clinics and specialized reproductive health centers.
• Healthcare providers offering assisted reproductive technologies.
• Patients seeking fertility treatments, particularly those interested in in vivo options.
• Individuals and couples facing infertility challenges globally.

FY2026 estForward Outlook

Wall Street analysts project INVO Bioscience, Inc. revenue of about $45.3M for fiscal 2026, with EPS near $0.19.

F-Score 5/9Financial Health

INVO Bioscience, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -5.39 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

Return on assets is -46.5%, showing how much profit it generates from its asset base. A current ratio of 0.90 means current liabilities exceed short-term assets, a liquidity point worth watching.

INVO Bioscience, Inc. (INVO) Valuation Context

Valued at $3.25M, INVO is classified as a micro-cap stock. Relative to its peer group, INVO's quantitative score of 62/100 is roughly in line with the peer average of 70/100.

Company Profile

INVO Bioscience, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Sarasota, US. The company is led by CEO Steven M. Shum. INVO has traded publicly since 2020.

INVO Financials

INVO Latest News

INVO Analyst Consensus

INVO MoonshotScore

Common Questions About INVO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources